Early- and Late-Stage Clinical Trials for the Spectrum of Alzheimer's Disease/Alzheimer's Disease-Related Dementias and Age-Related Cognitive Decline
Funding Amount
Not stated
Deadline
Forecast — dates not yet posted
Grant Type
Federal
Can we apply?
Check your organization against each line. Taken from the listing; confirm with the funder's guidelines.
Eligible organizations
- Public colleges & universities
- Private colleges & universities
- Nonprofits (501(c)(3))
- State governments
- County governments
- Public & Indian housing authorities
- School districts
- Small businesses
Overview
The National Institute on Aging (NIA) intends to publish a Notice of Funding Opportunity (NOFO) to 1) invite applications that propose to develop and implement early- to late-stage clinical trials of promising pharmacological and non-pharmacological interventions to prevent and/or treat the cognitive, behavioral, and neuropsychiatric changes associated with age-related cognitive decline and Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD), and 2) stimulate studies to enhance trial design and methods. Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. This NOFO intends to utilize the R01 activity code. Investigators with expertise and insights into this area of aging research are encouraged to begin to consider applying for this new NOFO.
Details
- Agency: National Institutes of Health
- Department: Department of Health and Human Services
- Opportunity #: FOR-RFA-AG-26-020
- Instrument: grant
Focus Areas & Funding Uses
Fields of Work
- Alzheimer's
- Science research
Categories
Browse similar grants by category
Related Grants
Open grants from this funder and similar programs
Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Clinical Centers (U01 Clinical Trial Required)
National Institutes of Health
Amount
Up to $1M
Deadline
October 9, 2026
Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Research Coordinating Center (U24 Clinical Trial Not Allowed)
National Institutes of Health
Amount
Varies
Deadline
October 9, 2026
Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed)
National Institutes of Health
Amount
$650,000 total
Deadline
October 9, 2026
Addressing Methodological Challenges with Clinical Trials of Rapid-Acting Psychotropic Interventional Drugs (RAPIDs) (R01 Clinical Trial Required)
National Institutes of Health
Amount
$5,000,000 total
Deadline
October 11, 2026
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
National Institutes of Health
Amount
Varies
Deadline
October 14, 2026
Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed)
National Institutes of Health
Amount
Varies
Deadline
October 14, 2026
Ready to apply for Early- and Late-Stage Clinical Trials for the Spectrum of Alzheimer's Disease/Alzheimer's Disease-Related Dementias and Age-Related Cognitive Decline?
Grantable helps you assess fit, draft narratives, and track deadlines — so you can submit stronger applications, faster.
You found Early- and Late-Stage Clinical Trials for the Spectrum of Alzheimer's Disease/Alzheimer's Disease-Related Dementias and Age-Related Cognitive Decline. Now let's win it.